

Northwest Portland Area Indian Health Board Indian Leadership for Indian Health

HCV Treatment Monitoring: Keeping it Simple

Paulina Deming, PharmD, PhC, RPh Associate Director Viral Hepatitis Clinics, ECHO Associate Director, College of Pharmacy University of New Mexico Health Sciences Center

August 16, 2023

Presentation prepared by: Date prepared:

Conflict of Interest Disclosure Statement

No relevant COI

Objectives

- List baseline laboratories recommended for HCV treatment evaluation
- Differentiate patients eligible for simplified monitoring
- Discuss HCV treatment monitoring recommendations



AASLD Guidance on HCV Treatment: Baseline Assessment

- Stage hepatic fibrosis
 - Does the patient have cirrhosis?
- Assess potential drug/drug interactions
- Educate patient about HCV medication

AASLD HCV Guidelines. https://www.hcvguidelines.org/evaluate/monitoring

Accessed August 16, 2023



AASLD Guidance on HCV Treatment: Baseline Laboratories

- Baseline laboratories (within 6 months)
 - CBC
 - INR
 - Hepatic panel: albumin, total and direct bilirubin, ALT, AST, ALK phos
 - Estimated GFR
- Document (any time prior to start of treatment)
 - HCV RNA
 - Hepatitis B serologies: anti-HBc, anti-HBs, HBsAg
 - Anti-HIV

AASLD HCV Guidelines. https://www.hcvguidelines.org/evaluate/monitoring Accessed August 16, 2023



"if a nonpangenotypic DAA will be prescribed, then test for HCV genotype and subtype"

AASLD HCV Guidelines. https://www.hcvguidelines.org/evaluate/monitoring Accessed August 16, 2023



Using the Simplified Treatment Algorithm

- Who is Eligible?
 - Adults with hepatitis C (any genotype) who do NOT have cirrhosis and have previously not received HCV treatment
- Who Is NOT Eligible?
 - Prior HCV treatment
 - Cirrhosis
 - HBsAg positive
 - Currently pregnant
 - Known or suspected hepatocellular carcinoma
 - Prior liver transplantation

AASLD HCV Guidelines.

https://www.hcvguidelines.org/evaluate/monitoring

Accessed August 16, 2023



Simplified Approach to Managing Patient with Cirrhosis

- Who is Eligible?
 - Adults with HCV who have compensated cirrhosis and have not previously been treated for HCV
 - Patients with a FIB-4 score >3.25 OR
 - Any of the following from previously performed test:
 - Transient elastography >12.5 kPa
 - Clinical evidence of cirrhosis (liver nodularity and/or splenomegaly on imaging, platelets <150,000 mm³, etc)
 - Prior liver biopsy showing cirrhosis
 - Liver biopsy is not required

AASLD HCV Guidelines.

https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis



Who Is NOT Eligible for Simplified Monitoring for Patients with Cirrhosis


- Patients with any of the following:
 - Current or prior episode of decompensation cirrhosis defined as CTP scores <a>?? (ascites, hepatic encephalopathy, total bilirubin >2 mg/dL, albumin < 3.5 g/dL, or INR <a>???)
 - Prior HCV treatment
 - End stage renal disease
 - HBsAg positive
 - Current pregnancy
 - Known or suspected hepatocellular carcinoma
 - Prior liver transplantation

AASLD HCV Guidelines.

https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis



General Approach to HCV Treatment









Simplified HCV Treatment Algorithm, any Genotype





investigate for other causes of liver disease

General Approach to HCV Treatment





On-Treatment Monitoring for Patients with Cirrhosis

 "Providers may order blood tests to monitor for liver injury during treatment because hepatic decompensation (eg, jaundice, etc) occurs rarely among patients with cirrhosis receiving HCV antiviral treatment"

AASLD HCV Guidelines. https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis




Baseline Labs CBC Chem7 LFTs/HFP HCV RNA and GT Anti-HAV Anti-HBc (igG or total) Anti-HBs HBsAg Anti-HIV PT/INR (only if presumed cirrhosis)





HCV On-Treatment Monitoring*

EOT: End of Treatment, TW: Treatment Week, *Does not apply to patients on DAA therapy plus ribravirin



- Not recommended for most patients
- Exception: patients with 8-20 days of treatment interruptions to help guide management in these situations

AASLD HCV Guidelines.

https://www.hcvguidelines.org/treatment-naive/simplified-treatment-compensated-cirrhosis https://www.hcvguidelines.org/evaluate/monitoring#incomplete-adherence



Key Points

- Simplified treatment approach minimizes the need for ontreatment laboratory visits for most patients with HCV including patients without cirrhosis or those with compensated cirrhosis
 - Patients with compensated cirrhosis may benefit from q 4 week hepatic panel if clinically indicated
 - Patients who benefit from clinical visits for adherence or other purposes should continue to be seen
- All patients should have HCV RNA and hepatic panel repeated 12 weeks after last dose of HCV therapy to document HCV cure and to assess resolution of hepatic inflammation
 - Persistent elevation in hepatic enzymes after HCV cure warrants additional work-up for other causes of liver disease



Indian Country ECHO HCV

End of Presentation

Questions?







Northwest Portland Area Indian Health Board Indian Leadership for Indian Health